Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of RBD SARS-CoV-2 HBsAg VLP vaccine in healthy adults
PACTR202112597608463Phase 1Not yet recruiting
- Sponsor
- Serum Institute of India
- Start
- Dec 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Serum Institute of India. Primary endpoint: Safety and reactogenicity. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccineChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202112597608463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112597608463.